Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088125133> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3088125133 endingPage "S1038" @default.
- W3088125133 startingPage "S1038" @default.
- W3088125133 abstract "ALTER1202 trial, the phase II study has demonstrated that anlotinib significantly prolonged progress-free survival (PFS) in relapsed SCLC patients as 3rd or further line treatment. Here, we performed a comparative analysis for patients with liver metastases in the placebo and anlotinib group. Eligible either limited- or extensive-stage SCLC patients who failed ≥ 2 lines of chemotherapy were randomized 2:1 to receive anlotinib or placebo (12 mg QD from day 1 to 14 of a 21-day cycle) till progression or intolerable toxicity. The primary endpoint was PFS. This subgroup analysis was based on patients with liver metastases at baseline. There are 39 patients with liver metastases in anlotinib and placebo groups (27 vs 12). Anlotinib significantly improved median PFS (1.84 vs 0.71 months; HR =0.37; 95% CI, 0.17–0.81; P=0.0039) but not median overall survial (3.29 vs 1.91 months; HR = 0.54; 95% CI, 0.23–1.26; P =0.1042) comparing to placebo in patients with liver metastases at baseline. The objective response rate was 3.7% in the anlotinib group and 0% in the placebo group (P =0.9999). 11(40.74%) patients in the anlotinib group and 1 (8.33%) patients in the placebo group had stable disease. The disease control rate was significantly higher in the anlotinib group (44.4%) than in the placebo group (8.33%, P < 0.0173). There was no complete response in either group.The most common adverse events in anlotinib group were hypertension(40.74%), fatigue(29.63%), loss of appetite(22.22%) and loss of weight (22.22 %) while in placebo group were ALT elevation (33.33%) , AST elevation (33.33%) and fatigue(25.00%). Anlotinib, administrate as 3rd or further line treatment, was well-tolerated and significantly prolonged PFS of relapsed SCLC patients with liver metastases." @default.
- W3088125133 created "2020-10-01" @default.
- W3088125133 creator A5008440809 @default.
- W3088125133 creator A5013800481 @default.
- W3088125133 creator A5021139793 @default.
- W3088125133 creator A5026332517 @default.
- W3088125133 creator A5028631107 @default.
- W3088125133 creator A5030035495 @default.
- W3088125133 creator A5042537297 @default.
- W3088125133 creator A5048287456 @default.
- W3088125133 creator A5050913370 @default.
- W3088125133 creator A5078938441 @default.
- W3088125133 creator A5086270619 @default.
- W3088125133 date "2020-09-01" @default.
- W3088125133 modified "2023-10-17" @default.
- W3088125133 title "1791P Effect of anlotinib in advanced small cell lung cancer (SCLC) patients with liver metastases: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202)" @default.
- W3088125133 doi "https://doi.org/10.1016/j.annonc.2020.08.1552" @default.
- W3088125133 hasPublicationYear "2020" @default.
- W3088125133 type Work @default.
- W3088125133 sameAs 3088125133 @default.
- W3088125133 citedByCount "2" @default.
- W3088125133 countsByYear W30881251332022 @default.
- W3088125133 countsByYear W30881251332023 @default.
- W3088125133 crossrefType "journal-article" @default.
- W3088125133 hasAuthorship W3088125133A5008440809 @default.
- W3088125133 hasAuthorship W3088125133A5013800481 @default.
- W3088125133 hasAuthorship W3088125133A5021139793 @default.
- W3088125133 hasAuthorship W3088125133A5026332517 @default.
- W3088125133 hasAuthorship W3088125133A5028631107 @default.
- W3088125133 hasAuthorship W3088125133A5030035495 @default.
- W3088125133 hasAuthorship W3088125133A5042537297 @default.
- W3088125133 hasAuthorship W3088125133A5048287456 @default.
- W3088125133 hasAuthorship W3088125133A5050913370 @default.
- W3088125133 hasAuthorship W3088125133A5078938441 @default.
- W3088125133 hasAuthorship W3088125133A5086270619 @default.
- W3088125133 hasBestOaLocation W30881251331 @default.
- W3088125133 hasConcept C126322002 @default.
- W3088125133 hasConcept C141071460 @default.
- W3088125133 hasConcept C142724271 @default.
- W3088125133 hasConcept C143998085 @default.
- W3088125133 hasConcept C168563851 @default.
- W3088125133 hasConcept C187960798 @default.
- W3088125133 hasConcept C197934379 @default.
- W3088125133 hasConcept C203092338 @default.
- W3088125133 hasConcept C204787440 @default.
- W3088125133 hasConcept C27081682 @default.
- W3088125133 hasConcept C2776256026 @default.
- W3088125133 hasConcept C44249647 @default.
- W3088125133 hasConcept C71924100 @default.
- W3088125133 hasConcept C90924648 @default.
- W3088125133 hasConceptScore W3088125133C126322002 @default.
- W3088125133 hasConceptScore W3088125133C141071460 @default.
- W3088125133 hasConceptScore W3088125133C142724271 @default.
- W3088125133 hasConceptScore W3088125133C143998085 @default.
- W3088125133 hasConceptScore W3088125133C168563851 @default.
- W3088125133 hasConceptScore W3088125133C187960798 @default.
- W3088125133 hasConceptScore W3088125133C197934379 @default.
- W3088125133 hasConceptScore W3088125133C203092338 @default.
- W3088125133 hasConceptScore W3088125133C204787440 @default.
- W3088125133 hasConceptScore W3088125133C27081682 @default.
- W3088125133 hasConceptScore W3088125133C2776256026 @default.
- W3088125133 hasConceptScore W3088125133C44249647 @default.
- W3088125133 hasConceptScore W3088125133C71924100 @default.
- W3088125133 hasConceptScore W3088125133C90924648 @default.
- W3088125133 hasLocation W30881251331 @default.
- W3088125133 hasOpenAccess W3088125133 @default.
- W3088125133 hasPrimaryLocation W30881251331 @default.
- W3088125133 hasRelatedWork W1947591645 @default.
- W3088125133 hasRelatedWork W2553592838 @default.
- W3088125133 hasRelatedWork W2559946394 @default.
- W3088125133 hasRelatedWork W2809017255 @default.
- W3088125133 hasRelatedWork W2880621648 @default.
- W3088125133 hasRelatedWork W2913870965 @default.
- W3088125133 hasRelatedWork W3113250085 @default.
- W3088125133 hasRelatedWork W3155195005 @default.
- W3088125133 hasRelatedWork W3172359983 @default.
- W3088125133 hasRelatedWork W3212096909 @default.
- W3088125133 hasVolume "31" @default.
- W3088125133 isParatext "false" @default.
- W3088125133 isRetracted "false" @default.
- W3088125133 magId "3088125133" @default.
- W3088125133 workType "article" @default.